Disruption of ARID1B Recruitment to the Nuclear Pore Complex as a New Anticancer Therapeutic Strategy

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Triple-negative breast cancer (TNBC) is an aggressive subtype lacking effective targeted therapies.
• ARID1B, a SWI/SNF complex subunit, is implicated in high-grade malignancies and poor prognosis.
• The precise function and regulation of ARID1B in cancer remain largely unknown.

Purpose of the Study:

• To elucidate the role of ARID1B nuclear import in TNBC oncogenesis and drug resistance.
• To identify the molecular mechanisms governing ARID1B nuclear translocation.
• To evaluate the therapeutic potential of inhibiting ARID1B nuclear import in TNBC.

Main Methods:

• Protein complex purification and mass spectrometry to identify ARID1B interacting partners.
• Site-directed mutagenesis to disrupt ARID1B-protein interactions.
• Pharmacological inhibition of key nuclear import factors.
• ARID1B knockout mouse models and efficacy studies with PARP inhibitors.

Main Results:

• Uncontrolled ARID1B accumulation and nuclear import promote TNBC oncogenesis and drug resistance.
• ARID1B negatively regulates ARID1A, diminishing SWI/SNF tumor suppressor activity.
• The KPNA2-KPNB1-RANBP2 cascade is identified as critical for ARID1B nuclear import.
• Specific ARID1B residue mutations and KPNB1 inhibition block ARID1B nuclear translocation.
• ARID1B knockout reduces tumor growth and sensitizes TNBC to PARP inhibitors.

Conclusions:

• ARID1B nuclear translocation is a critical oncogenic driver in TNBC.
• Targeting ARID1B nuclear import, via KPNB1 inhibition or specific mutations, represents a novel therapeutic avenue.
• Blocking ARID1B nuclear translocation can overcome drug resistance and improve TNBC treatment outcomes.